• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Testosterone and Dihydrotestosterone and Incident Ischemic Stroke in Men in the Cardiovascular Health Study.
CONCLUSIONS: DHT had a nonlinear association with stroke risk in which there was an optimal DHT level associated with the lowest stroke risk. Further studies are needed to confirm these results and to clarify if there is an optimal androgen range associated with the least risk for adverse outcomes in elderly men. This article is protected by copyright. All rights reserved. PMID: 24645738 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - March 19, 2014 Category: Cancer & Oncology Authors: Shores MM, Arnold AM, Biggs ML, Longstreth WT, Smith NL, Kizer JR, Cappola AR, Hirsch CH, Marck BT, Matsumoto AM Tags: Clin Endocrinol (Oxf) Source Type: research

Incidental Uptake in a Subacute Stroke on 18F-Piflufolastat PSMA PET/CT
Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004798. Online ahead of print.ABSTRACTProstate-specific membrane antigen (PSMA) PET/CT has proven to be effective in the evaluation of prostate cancer and has become increasingly used clinically as multiple radiopharmaceuticals have become commercially available. With increasing use, incidental uptake from a variety of nononcologic processes will be encountered and considered interpretive pitfalls. We outline a case of a 71-year-old man who underwent imaging with PSMA PET/CT, which demonstrated uptake in the left parietal-temporal junction that was shown to be a subacut...
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Miles C Lewis Daniel J Wale Eric Liao Benjamin L Viglianti Source Type: research

Long-term Cardiovascular Risks of Gonadotropin-releasing Hormone Agonists and Antagonists: A Population-based Cohort Study
CONCLUSIONS: GnRH antagonists may be associated with higher long-term, but not short-term, cardiovascular risks than agonists in Asian patients with PCa, particularly in those without known cardiovascular risk factors.PMID:37031076 | DOI:10.1016/j.clon.2023.03.014
Source: Clinical Prostate Cancer - April 8, 2023 Category: Cancer & Oncology Authors: J S K Chan Y H A Lee J M H Hui K Liu E C Dee K Ng P Tang G Tse C F Ng Source Type: research

Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride.
CONCLUSION: We did not find consistent evidence of a significant association between dutasteride therapy and the risk of cardiovascular adverse events. PMID: 23815285 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - July 1, 2013 Category: Cancer & Oncology Authors: Loke YK, Ho R, Smith M, Wong O, Sandhu M, Sage W, Singh S Tags: J Clin Pharm Ther Source Type: research

Coronary Artery Bypass Grafting in Cancer Patients: Prevalence and Outcomes in the United States.
CONCLUSION: Among those undergoing CABG, the prevalence of comorbid cancer has steadily increased. Outside of major bleeding, these patients appear to share similar outcomes to those without cancer indicating that CABG utilization should be not be declined in cancer patients when otherwise indicated. Further research into the factors underlying the decision to pursue CABG in specific cancer sub-groups is needed. PMID: 32861331 [PubMed - in process]
Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Guha A, Dey AK, Kalra A, Gumina R, Lustberg M, Lavie CJ, Sabik JF, Addison D Tags: Mayo Clin Proc Source Type: research

Impact of Comorbidities on Lung Cancer Screening Evaluation
CONCLUSION: Patient and procedure-level factors may alter the benefits of lung cancer screening. Data concerning individual risk factors and high-risk complications should therefore be incorporated into diagnostic algorithms to optimize clinical benefit and minimize harm. Further study and validation of the risk factors identified herein are warranted.PMID:35641376 | DOI:10.1016/j.cllc.2022.03.012
Source: Clinical Prostate Cancer - May 31, 2022 Category: Cancer & Oncology Authors: Eric M Robinson Benjamin Y Liu Keith Sigel Chung Yin Juan Wisnivesky Minal S Kale Source Type: research

Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study.
CONCLUSION: The magnitude of subsequent CVD risk varies according to cancer subtype and by the presence of CVRFs. Overall survival in survivors who develop CVD is poor, emphasizing the need for targeted prevention strategies for individuals at highest risk of developing CVD. PMID: 26834065 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - February 1, 2016 Category: Cancer & Oncology Authors: Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C Tags: J Clin Oncol Source Type: research

Metastatic prostate cancer mimicking a subdural hematoma: A case report and literature review.
Abstract Occurrences of metastatic prostate cancer imitating a subdural hematoma are limited to a small number of case reports, even though prostate cancer spreads to the dura more than other types of cancer. Here, we present the case of a 64 year-old male whose prostate carcinoma's metastasis mimicked a subdural hematoma, and he suffered a middle cerebral artery stroke. Prostate cancer's high rate of progression to the dura is disproportionate to its relatively low rate of brain metastasis. Furthermore, we explore the potential molecular implications of prostate cancer's propensity to spread to the dura. P...
Source: Clinical Prostate Cancer - July 4, 2018 Category: Cancer & Oncology Authors: Nunno A, Johnson MD, Wu G, Li YM Tags: J Clin Neurosci Source Type: research

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research

Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
CONCLUSIONS: Our findings suggest that ABI users may be at greater risk of cardiovascular-related hospitalization compared to ENZ users, in particular for heart failure. These results provide clinicians with additional insight on the cardiovascular risks of mCRPC patients treated with NHAs in the real-world and further large studies are required to corroborate these findings.PMID:34706850 | DOI:10.1016/j.clgc.2021.08.009
Source: Clinical Prostate Cancer - October 28, 2021 Category: Cancer & Oncology Authors: Jason Hu Armen G Aprikian Marie Vanhuyse Alice Dragomir Source Type: research

Pages: 1  2